• Xenetic Biosciences disclosed an Israeli regulator green light for an exploratory investigator-run study pairing systemic DNase I with anti-CD19 CAR T therapy in LBCL.
• Preclinical findings have already been reported, showing the combination improved CAR T performance and tumor control in hematologic cancer models.
• The trial will enroll 12 patients with stable or progressive disease at lymphodepletion, targeting earlier relapse risk seen with current CAR T use.
• Efficacy readouts will be presented in the future, tracking whether the add-on approach translates into better response durability and survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.